ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 20 Issue : 3
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study [Anatol J Cardiol]
Anatol J Cardiol. 2014; 14(2): 121-127 | DOI: 10.5152/akd.2014.4834  

Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study

Necla Özer1, Hikmet Yorgun1, Uğur Canpolat2, Bülent Elibol3
1Department of Cardiology, Faculty of Medicine, Hacettepe University, Ankara-Turkey
2Department of Cardiology, Faculty of Medicine, Hacettepe University, Ankara-Turkey
3Department of Cardiology Neurology, Faculty of Medicine, Hacettepe University, Ankara-Turkey

Objective: In this study, we aimed to evaluate the impact of cabergoline use in patients with Parkinson’s disease on valvular and biventricular functions. Methods: In this observational cohort study, patients with Parkinson disease were divided into 2 groups as 34 patients (41.2% female, age; 57.4±15.3 years) using cabergoline (Group 1) and 42 patients (61.9% female, age; 53.7±7.1 years) not using cabergoline (Group 2). In addition to conventional echocardiography and diastolic functions, tissue Doppler imaging was used to evaluate both global and regional systolic - diastolic functions. Correlations were assessed using Pearson correlation coefficient for normally distributed variables. Results: In group 1 patients cabergoline was used for 7.7±5.1 years and mean and cumulative cabergoline dose were 3.3±1.1 mg and 9.8±7.0 g respectively. Left ventricular systolic functions and tissue Doppler measurements of septal and lateral mitral annulus and right ventricular systolic and diastolic velocities were similar between groups. Mitral valve tenting area was significantly higher in patients using cabergoline (p=0.007). The association between cumulative cabergoline dose and diastolic functions was also evaluated which revealed that among diastolic function parameters, Epeak (r=0.253, p=0.042), E/A (r=0.256, p=0.026) and DT (r=-0.382, p=0.001) were correlated with cumulative cabergoline dose. There was a positive correlation between cumulative cabergoline dose and duration of cabergoline therapy with composite regurgitation score (r=0.435, p<0.001; r=0.485, p<0.001, respectively). Conclusion: Our findings indicated that despite the well known effects of cabergoline on valvular functions, we did not observe any alteration in systolic functions, but diastolic functions which was associated with cumulative cabergoline dose in patients with Parkinson’s disease.

Keywords: Parkinson disease, cabergoline, valvular, ventricular function


Ergotamin türevi dopamin agonisti kullanan Parkinson hastalarında kapak ve biventriküler işlevlerin değerlendirilmesi: Gözlemsel bir çalışma

Necla Özer1, Hikmet Yorgun1, Uğur Canpolat2, Bülent Elibol3
1Department of Cardiology, Faculty of Medicine, Hacettepe University, Ankara-Turkey
2Department of Cardiology, Faculty of Medicine, Hacettepe University, Ankara-Turkey
3Department of Cardiology Neurology, Faculty of Medicine, Hacettepe University, Ankara-Turkey

Amaç: Bu çalışmada Parkinson hastalarında kabergolin kullanımının valvüler ve biventriküler işlevler üzerine etkisinin değerlendirilmesi amaçlanmıştır. Yöntemler: Bu gözlemsel kohort çalışmasında Parkinson hastaları 2 gruba ayrılmıştır; kabergolin kullanan 34 hasta (%41,2 kadın, yaş; 57,4±15,3 yıl) (Grup 1) ve kabergolin kullanmayan yeni tanı alan 42 hasta (%61,9 kadın, yaş; 53,7±7,1 yıl) (Grup 2). Konvansiyonel ekokardiyografik ve diyastolik parametrelere ek olarak, global ve bölgesel sistolik - diyastolik fonksiyonların değerlendirilmesi için doku Doppler görüntüleme kullanıldı. Normal dağılım gösteren değişkenler arası ilişki Pearson korelasyon katsayısı ile değerlendirildi. Bulgular: Grup 1 hastaları ortalama 7,7±5,1 yıldır kabergolin kullanıyordu; ortalama ve kümülatif kabergolin dosu 3,3±1,1 mg ve 9,8±7,0 gr idi. Sol ventrikül sistolik fonksiyonu ve doku Doppler ölçümlerinde septal ve lateral mitral anülüs ve sağ ventriküler sistolik ve diyastolik hızlar gruplar arasında benzerdi. Mitral kapak çadırlaşma alanı kabergolin kullanan grupta anlamlı olarak yüksekti (p=0,007). Kümülatif kabergolin dozu ve diyastolik fonksiyonlar arasındaki ilişki değerlendirildiğinde; Etepe (r=0,253, p=0,042), E/A (r=0,256, p=0,026) ve DZ (r=-0,382, p=0,001) kümülatif kabergolin dozu ile anlamlı korelasyona sahipti. Ayrıca kümülatif kabergolin dozu ve kabergolin tedavisi süresi ile birleşik regürjitasyon skoru arasında pozitif korelasyon saptandı (r=0,435, p<0,001; r=0,485, p<0,001). Sonuç: Kabergolin tedavisinin kapak fonksiyonları üzerine olumsuz etkileri iyi bilinirken, bu çalışmada Parkinson hastalarında kabergolin tedavisinin sistolik fonksiyonlar üzerine belirgin etkisi gözlenmemiştir, ancak diyastolik fonksiyonda bozulma kümülatif kabergolin dozu ile ilişkili bulunmuştur.

Anahtar Kelimeler: Parkinson disease, cabergoline, valvular, ventricular function


Necla Özer, Hikmet Yorgun, Uğur Canpolat, Bülent Elibol. Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anatol J Cardiol. 2014; 14(2): 121-127


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology